ccRCC

13 registered clinical trials studyying ccRCC — 5 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Pembrolizumab Plus Lenvatinib in REcurrent ccRCC Patients Failing permbroLizUmab aDjuvant trEatment NCT07460206	Gruppo Oncologico Italiano di Ricerca Clinica	Phase 2
Recruiting	Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC NCT07197580	Telix Pharmaceuticals (Innovations) Pty Limited	Phase 3
Not Yet Recruiting	CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC NCT07077083	Massachusetts General Hospital	Phase 2
Recruiting	Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cel NCT07300241	Neomorph, Inc	Phase 1
Not Yet Recruiting	68Ga-NYM096 PET/ CT for the Detection of ccRCC in Presurgical Patients With Complex Cystic Renal Leision NCT06949215	Peking Union Medical College Hospital	Phase 2
Terminated	Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccR NCT05935748	NiKang Therapeutics, Inc.	Phase 2
Terminated	A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma NCT05119335	NiKang Therapeutics, Inc.	Phase 1 / Phase 2
Terminated	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors NCT03875313	Calithera Biosciences, Inc	Phase 1 / Phase 2
Completed	MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK NCT03108066	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 2
Active Not Recruiting	A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) NCT02974738	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 1
Active Not Recruiting	A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma ( NCT02293980	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Phase 1
Completed	Prognostic Significance of the Lung Immune Prognostic Index (LIPI) in Postoperative Clear Cell Renal Cell Carc NCT06775574	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	—
Completed	Visceral Fat Area as a Prognostic Biomarker in Clear Cell Renal Cell Carcinoma: A Multicenter Study on Postope NCT06791863	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	—